Micropthalmia Transcription Factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 8, 2013, Pages 1658-1664

  Guo, Ruifeng ^a   Franco Palacios, Maria ^a   Russell, Madison ^a   Goddard, Lindsey ^a   Hassell, Lewis ^a   Gillies, Elizabeth ^a   Fung, Kar Ming ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Immunohistochemistry; Melanoma; Microphthalmia Transcription Factor

Indexed keywords

MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; TUMOR MARKER;

AGED; ARTICLE; BIOSYNTHESIS; CASE REPORT; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METABOLISM; SKIN TUMOR; VERY ELDERLY;

IMMUNOHISTOCHEMISTRY; MELANOMA; MICROPHTHALMIA TRANSCRIPTION FACTOR;

AGED; AGED, 80 AND OVER; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882992134     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kyrgidis A, Tzellos TG and Triaridis S. Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinog 2010; 9: 3.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Sheffield MV, Yee H, Dorvault CC, Weilbaecher KN, Eltoum IA, Siegal GP, Fisher DE and Chhieng DC. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol 2002; 118: 930-936.
4. Xu X, Chu AY, Pasha TL, Elder DE and Zhang PJ. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol 2002; 26: 82-87.
5. Riddle ND and Bui MM. When melanoma is negative for S100: diagnostic pitfalls. Arch Pathol Lab Med 2012; 136: 237-239.
6. Sheth A and Arsenovic N. Melanoma markers-negative primary melanoma with melanoma markers-positive metastasis. Int J Surg Pathol 2011; 19: 127-130.
7. Prieto VG and Shea CR. Immunohistochemistry of melanocytic proliferations. Arch Pathol Lab Med 2011; 135: 853-859.
8. Chang KL and Folpe AL. Diagnostic utility of microphthalmia transcription factor in malignant melanoma and other tumors. Adv Anat Pathol 2001; 8: 273-275.
9. Ohsie SJ, Sarantopoulos GP, Cochran AJ and Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008; 35: 433-444.
10. Vachtenheim J and Borovansky J. Microphthalmia transcription factor: a specific marker for malignant melanoma. Prague Med Rep 2004; 105: 318-324.
11. Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J and Sarlomo-Rikala M. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol 2001; 25: 205-211.
12. Granter SR, Weilbaecher KN, Quigley C and Fisher DE. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol 2002; 10: 47-51.
13. Makhlouf HR, Ishak KG, Shekar R, Sesterhenn IA, Young DY and Fanburg-Smith JC. Melanoma markers in angiomyolipoma of the liver and kidney: a comparative study. Arch Pathol Lab Med 2002; 126: 49-55.
14. King R, Googe PB, Weilbaecher KN, Mihm MC Jr and Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 2001; 25: 51-57.
15. Busam KJ, Iversen K, Coplan KC and Jungbluth AA. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25: 197-204.
16. Koch MB, Shih IM, Weiss SW and Folpe AL. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. Am J Surg Pathol 2001; 25: 58-64.
17. Pakneshan S, Salajegheh A, Smith RA and Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013; 45: 346-356.
18. Kudchadkar RR, Smalley KS, Glass LF, Trimble JS and Sondak VK. Targeted therapy in melanoma. Clin Dermatol 2013; 31: 200-208.
19. Flaherty KT, Hodi FS and Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol 2010; 22: 178-183.
20. Wang JF, Sarma DP, Ulmer P. Diagnostic dilemma: HMB-45 and Melan-A negative tumor, can it be still a melanoma?: MITF (Microphthalmia-associated transcription factor) stain may confirm the diagnosis. The Internet Journal of Dermatology 2007; 5.